KALA BIO, Inc. KALA BIO, Inc.

KALA BIO, Inc.

KALA

Rank in Stocks #30846
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the... Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Share Price
$0.75
Last synced: 2026-07-31
Market Cap
$14.50M
Change (1 day)
2.78%
Change (1 year)
-98.52%
Country
US
Trade KALA BIO, Inc. (KALA)

Category

Healthcare
P/E ratio for KALA BIO, Inc. (KALA)
P/E ratio as of 2026 TTM: 0
According to KALA BIO, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for KALA BIO, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.78 -
US
-28.36 -
US
-24.57 -
AU
- -
CH
30.33 -
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.